Boehringer Ingelheim Pharmaceuticals, Inc.

182 articles with Boehringer Ingelheim Pharmaceuticals, Inc.

• Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes

  9/14/2012

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: RE-LY Sub-Analysis Suggests Pradaxa® (Dabigatran Etexilate Mesylate) Associated With Similar Bleeding Rates And Thromboembolic Complications In Surgery Versus Warfarin

  6/18/2012

• Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. Present Data at the 72nd Boehringer Ingelheim Pharmaceuticals, Inc. Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine

  6/12/2012

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: Pradaxa(R) (dabigatran etexilate mesylate) U.S. Label Now Affirms Superior Reduction in Ischemic and Hemorrhagic Stroke Versus Warfarin in Patients with Non-Valvular Atrial Fibrillation

  6/6/2012

• Boehringer Ingelheim Pharmaceuticals, Inc. and CancerCare® Launch My Cancer Circle™ Online Tool for Cancer Caregivers

  6/1/2012

• Results of Phase II Study of Boehringer Ingelheim Pharmaceuticals, Inc.'s Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference

  5/21/2012

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: National Survey Reveals Constipation is One of the Least Discussed Women's Health Issues

  5/16/2012

• Boehringer Ingelheim Pharmaceuticals, Inc. Announces Launch of GLORIA(TM)-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation

  5/3/2012

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa(R) (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial

  4/19/2012

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: Dabigatran Etexilate (Pradaxa®) Associated with Significantly Lower Rates of Fatal and Traumatic Intracranial Haemorrhage Compared with Warfarin

  4/18/2012

• Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company's New Oral Type 2 Diabetes Treatment for Adults, Jentadueto™ (linagliptin/metformin hydrochloride) Tablets, Now Available in U.S. Pharmacies

  3/7/2012

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: Colon Cancer Alliance and Dulcolax(R) Encourage Americans to Be a Lifesaver and Get Screened for Colon Cancer

  3/1/2012

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: Study Finds No Drug-Drug Interaction Between Aggrenox(R) (aspirin/extended-release dipyridamole) 25mg/200mg Capsules and Omeprazole, a Widely Used PPI

  2/6/2012

• Boehringer Ingelheim Pharmaceuticals, Inc. Invests More Than $350 Million in 2011 U.S. Expansion Projects

  11/15/2011

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Subanalyses of RE-LY(R) Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation

  11/14/2011

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types

  11/8/2011

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: BI 201335 Demonstrates Potential toShorten HCV Treatment Duration While Achieving High Sustained Virological Response Rates in Difficult to Treat Patients

  11/8/2011

• Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheim Pharmaceuticals, Inc.'s Two Investigational HCV Direct Acting Antivirals Presented at Boehringer Ingelheim Pharmaceuticals, Inc.

  11/7/2011

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: Runners Take to the Streets in Undies to Fight Colon Cancer

  10/24/2011

• Boehringer Ingelheim Pharmaceuticals, Inc. Release: Interim Data Announced for BIBF 1120 as Compared to Bevacizumab in Combination Chemotherapy in Metastatic Colorectal Cancer

  9/27/2011